A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate.
暂无分享,去创建一个
B. Graham | M. Chen | J. S. Chang | M. Nason | D. Rangel | J. Gall | J. Ledgerwood | J. S. Chang | M. Chen
[1] C. Andrewes,et al. Observations on Anti-Phage Sera. I: “The Percentage Law” , 1933 .
[2] A. Frank,et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. , 1981, The Journal of pediatrics.
[3] J. Hierholzer,et al. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay , 1985, Journal of clinical microbiology.
[4] M. Perkins,et al. Primary respiratory syncytial virus infection in mice , 1988, Journal of medical virology.
[5] D. Pfarr,et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. , 1997, The Journal of infectious diseases.
[6] P. Collins,et al. Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. , 2000, Virology.
[7] Q. Sattentau,et al. Mechanisms of virus neutralization by antibody. , 2001, Current topics in microbiology and immunology.
[8] J. Mascola,et al. Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells , 2002, Journal of Virology.
[9] R. Doms,et al. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. , 2006, Virology.
[10] B. Graham,et al. Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis , 2007, Journal of Virology.
[11] M. Fay,et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. , 2007, The Journal of infectious diseases.
[12] J. Mascola,et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial , 2008, Vaccine.
[13] T. Pierson,et al. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. , 2009, Virology.